Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | XDH | P47989 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498605 | 0.82 | MAOB (0.70) | MAOBXDHMAOA | |
| SCHEMBL1331634 | 0.81 | MAOB (0.56) | MAOBXDH | |
| SCHEMBL7929558 | 0.80 | AR (0.44) | MAOBXDHMAOA | |
| SCHEMBL3648539 | 0.79 | MAOB (1.00) | MAOBMAOAIMPDH2 | |
| SCHEMBL4770223 | 0.79 | LIPE (0.46) | — | |
| SCHEMBL3382509 | 0.79 | MAOB (0.60) | MAOBXDHMAOA | |
| SCHEMBL30711914 | 0.78 | SMPD1 (0.56) | — | |
| SCHEMBL7929493 | 0.78 | ALDH1A1 (0.48) | MAOBXDHMAOA | |
| SCHEMBL5902106 | 0.78 | MAOB (0.78) | MAOBXDHMAOAIMPDH2 | |
| SCHEMBL9430700 | 0.77 | MAOB (0.68) | MAOBXDHMAOAIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | MAOB 350/4885XDH 1/4885MAOA 214/4885 |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | XDH, NLRP3, UACA | MAOB 268/4885XDH 1/4885MAOA 384/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | MAOB 350/4885XDH 1/4885MAOA 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.